Suppr超能文献

相似文献

1
Innate immune evasion mediated by picornaviral 3C protease: Possible lessons for coronaviral 3C-like protease?
Rev Med Virol. 2021 Sep;31(5):1-22. doi: 10.1002/rmv.2206. Epub 2021 Jan 7.
2
Picornaviral 3C protease inhibitors and the dual 3C protease/coronaviral 3C-like protease inhibitors.
Expert Opin Ther Pat. 2010 Jan;20(1):59-71. doi: 10.1517/13543770903460323.
3
Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases.
FEBS J. 2021 Sep;288(17):5089-5121. doi: 10.1111/febs.15696. Epub 2021 Feb 1.
4
Identification of Host Cellular Protein Substrates of SARS-COV-2 Main Protease.
Int J Mol Sci. 2020 Dec 15;21(24):9523. doi: 10.3390/ijms21249523.
5
7
Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity.
J Virol. 2021 Jun 24;95(14):e0237420. doi: 10.1128/JVI.02374-20.
9
The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
Biochem Biophys Res Commun. 2022 Feb 5;591:130-136. doi: 10.1016/j.bbrc.2020.12.106. Epub 2021 Jan 6.
10
SARS-CoV-2 3CL displays faster self-maturation in vitro than SARS-CoV 3CL due to faster C-terminal cleavage.
FEBS Lett. 2022 May;596(9):1214-1224. doi: 10.1002/1873-3468.14337. Epub 2022 Mar 28.

引用本文的文献

1
SADS-CoV nsp5 Inhibits Interferon Production by Targeting Kinase IKKε.
Microorganisms. 2025 Jun 26;13(7):1494. doi: 10.3390/microorganisms13071494.
2
Porcine Teschovirus 2 3C Evades Host Antiviral Innate Immunity by Inhibiting the IFN-β Signaling Pathway.
Microorganisms. 2025 May 26;13(6):1209. doi: 10.3390/microorganisms13061209.
4
On the origins of SARS-CoV-2 main protease inhibitors.
RSC Med Chem. 2023 Oct 13;15(1):81-118. doi: 10.1039/d3md00493g. eCollection 2024 Jan 25.
6
Seneca Valley virus 3C antagonizes host innate immune responses and programmed cell death.
Front Microbiol. 2023 Oct 6;14:1235620. doi: 10.3389/fmicb.2023.1235620. eCollection 2023.
7
10
Seneca Valley Virus Induces DHX30 Cleavage to Antagonize Its Antiviral Effects.
J Virol. 2022 Sep 14;96(17):e0112122. doi: 10.1128/jvi.01121-22. Epub 2022 Aug 24.

本文引用的文献

2
Type I Interferon Susceptibility Distinguishes SARS-CoV-2 from SARS-CoV.
J Virol. 2020 Nov 9;94(23). doi: 10.1128/JVI.01410-20.
3
Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.
Nature. 2020 Sep;585(7826):588-590. doi: 10.1038/s41586-020-2575-3. Epub 2020 Jul 22.
4
5
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.
Cell. 2020 May 28;181(5):1036-1045.e9. doi: 10.1016/j.cell.2020.04.026. Epub 2020 May 15.
6
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Nature. 2020 Jul;583(7816):459-468. doi: 10.1038/s41586-020-2286-9. Epub 2020 Apr 30.
7
A rampage through the body.
Science. 2020 Apr 24;368(6489):356-360. doi: 10.1126/science.368.6489.356.
8
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.
Science. 2020 Jun 19;368(6497):1331-1335. doi: 10.1126/science.abb4489. Epub 2020 Apr 22.
9
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
N Engl J Med. 2020 Jun 11;382(24):2327-2336. doi: 10.1056/NEJMoa2007016. Epub 2020 Apr 10.
10
Structure of M from SARS-CoV-2 and discovery of its inhibitors.
Nature. 2020 Jun;582(7811):289-293. doi: 10.1038/s41586-020-2223-y. Epub 2020 Apr 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验